Cytokine gene polymorphism in human disease: On-line databases

Genes and Immunity

Volumn 1, Issue 1, 1999, Pages 3-19

  Bidwell, J ^a   Keen, L ^a   Gallagher, G ^b   Kimberly, R ^c   Huizinga, T ^d   McDermott, M F ^e   Oksenberg, J ^f   McNicholl, J ^g   Pociot, F ^h   Hardt, C ⁱ   D'Alfonso, S ^j  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c The University of Alabama at Birmingham   (United States)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^h STENO DIABETES CENTER   (Denmark)

ⁱ UNIVERSITY HOSPITAL ESSEN   (Germany)

^j UNIVERSITY OF EASTERN PIEDMONT   (Italy)

more..

Author keywords

Cytokines; Gene expression; Gene polymorphism

Indexed keywords

CYTOKINE;

CHEMISTRY; FACTUAL DATABASE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETICS; HUMAN; IMMUNOLOGY; IN VITRO STUDY; INTERNET; REVIEW; TH1 CELL; TH2 CELL;

CYTOKINES; DATABASES, FACTUAL; GENE EXPRESSION; HUMANS; INTERNET; POLYMORPHISM, GENETIC; TH1 CELLS; TH2 CELLS;

EID: 0033188361     PISSN: 14664879     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gene.6363645     Document Type: Article

References (323)

1. Hibi M, Hirano T. Signal transduction through cytokine receptors. Int Rev of Immunol 1998; 17: 75-102.
2. Onishi M, Nosaka T, Kitamura T. Cytokine receptors: structures and signal transduction. Int Rev of Immunol 1998; 16: 617-634.
3. Rubinstein M, Dinarello CA, Oppenheim JJ, Hertzog P. Recent advances in cytokines, cytokine receptors and signal transduction. Cytokine and Growth Factor Rev 1998; 9: 175-181.
4. Carpenter LR, Yancopoulos GD, Stahl N. General mechanisms of cytokine receptor signaling. Adv Protein Chem 1998; 52: 109-140.
5. Ihle JN, Thierfelder W, Teglund S et al. Signaling by the cytokine receptor superfamily. Ann NY Acad Sci 1998; 865: 1-9.
6. Casciari JJ, Sato H, Durum SK, Fiege J, Weinstein JN. Reference databases of cytokine structure and function. Cancer Chemother Biolog Response Modifiers 1996; 16: 315-346.
7. Minasian E, Nicola NA. A review of cytokine structures. Protein Sequences and Data Analysis 1992; 5: 57-64.
8. Balkwill FR, Burke F. The cytokine network. Immunology Today 1989; 10: 299-304.
9. Elias JA, Zitnik RJ. Cytokine-cytokine interactions in the context of cytokine networking. Am J Respirat Cell Molecul Biol 1992; 7: 365-367.
10. Fraser JK, Lill MC, Figlin RA. The biology of the cytokine sequence cascade. Seminars in Oncology 1996; 23: 2-8.
11. Kunkel S, Standiford T, Chensue SW, Kasahara K, Strieter RM. Cellular and molecular mechanisms of cytokine networking. Agents And Actions. Supplements 1991; 32: 205-218.
12. Olsson I. The cytokine network. J Intern Med 1993; 233: 103-105.
13. Abbas AK, Williams ME, Burstein HJ, Chang TL, Bossu P, Lichtman AH. Activation and functions of CD4+ T-cell subsets. Immunol Rev 1991; 123: 5-22.
14. HayGlass KT, Wang M, Gieni RS, Ellison C, Gartner J. In vivo direction of CD4 T cells to Th1 and Th2-like patterns of cytokine synthesis. Advances in Experiment Med and Biol 1996; 409: 309-316.
15. Kapsenberg ML, Wierenga EA, Bos JD, Jansen HM. Functional subsets of allergen-reactive human CD4+ T cells. Immunol Today 1991; 12: 392-395.
16. Kelso A, Troutt AB, Maraskovsky E et al. Heterogeneity in lymphokine profiles of CD4+ and CD8+ T cells and clones activated in vivo and in vitro. Immunolog Rev 1991; 123: 85-114.
17. Lederer JA, Liou JS, Todd MD, Glimcher LH, Lichtman AH. Regulation of cytokine gene expression in T helper cell subsets. J Immunol 1994; 152: 77-86.
18. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17: 138-146.
19. Williams ME, Chang TL, Burke SK, Lichtman AH, Abbas AK. Activation of functionally distinct subsets of CD4+ T lymphocytes. Res Immunol 1991; 142: 23-28.
20. Mosmann TR. Cytokine secretion patterns and cross-regulation of T cell subsets. Immunol Res 1991; 10: 183-188.
21. Hässig A, Kremer H, Liang WX, Stampfli K. The role of the Th-1 to Th-2 shift of the cytokine profiles of CD4 helper cells in the pathogenesis of autoimmune and hypercatabolic diseases. Med Hypotheses 1998; 51: 59-63.
22. Cunha-Neto E, Rizzo LV, Albuquerque F et al. Cytokine production profile of heart-infiltrating T cells in Chagas' disease cardiomyopathy. Brazilian J Med Biolog Res 1998; 31: 133-137.
23. Shearer GM, Clerici M. Cytokine profiles in HIV type 1 disease and protection. Aids Res and Human Retroviruses 1998; 14 (Suppl 2): S149-152.
24. Miossec P, van den Berg W. Th1/Th2 cytokine balance in arthritis. Arthritis and Rheumatism 1997; 40: 2105-2115.
25. Karban A, Lerner A, Shapiro S. Th1/TH2 cytokine profile in celiac disease. Israel J Med Sci 1997; 33: 209-214.
26. Wu TC, Kurman RJ. Analysis of cytokine profiles in patients with human papillomavirus-associated neoplasms. J Nat Cancer Inst 1997; 89: 185-187.
27. Rugtveit J, Nilsen EM, Bakka A, Carlsen H, Brandtzaeg P, Scott H. Cytokine profiles differ in newly recruited and resident subsets of mucosal macrophages from inflammatory bowel disease. Gastroenterology 1997; 112: 1493-1505.
28. Groux H, Rouleau M, Bacchetta R, Roncarolo MG. T-cell subsets and their cytokine profiles in transplantation and tolerance. Annals of the New York Acad of Sci 1995; 770: 141-148.
29. Miossec P. Acting on the cytokine balance to control autoimmunity and chronic inflammation. Eur Cytokine Netw 1993; 4: 245-251.
30. Miossec P. Pro-and antiinflammatory cytokine balance in rheumatoid arthritis. Clin Exp Rheumatol 1995; 13 (Suppl 12): S13-16.
31. Rabinovitch A. Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM. Therapeutic intervention by immunostimulation? Diabetes 1994; 43: 613-621.
32. Bidwell JL, Wood NAP, Morse HR, Olomolaiye OO, Laundy GJ. Human cytokine gene nucleotide sequence alignments, 1998. Eur J Immunogenet 1998; 25: 83-266.
33. Bidwell JL, Wood NAP, Morse HR, Olomolaiye OO, Keen LJ, Laundy GJ. Human cytokine gene nucleotide sequence alignments: supplement 1. Eur J Immunogenet 1999; 26: 135-223.
34. Bidwell JP. Nuclear matrix proteins and osteoblast gene expression. J Bone Miner Res 1998; 13: 155-167.
35. Escamilla MA, McInnes LA, Spesney M, Reus VI, Service SK, Shimayoshi N. Assessing the feasibility of linkage disequilibrium methods for mapping complex traits: an initial screen for bipolar disorder loci on chromosome 18. Am J Hum Genet 1999; 64: 1670-1678.
36. Spielman RS, McGinnis RE, Ewens WJ. Transmission test for linkage disequilibrium the insulin gene and insulin-dependent diabetes mellitus (IDDM). Am J Hum Genet 1993; 52: 506-516.
37. Sham PC, Curtis D. An extended transmission/disequilbrium test (TDT) for multi-allele marker loci. Am J Hum Genet 1995; 59: 323-336.
38. Merriman TR, Eaves IA, Twells RC, Merriman ME, Danoy PA, Muxworthy CE. Transmission of haplotypes of microsatellite markers rather than single marker alleles in the mapping of putative type 1 diabetes susceptibility gene (IDDM6). Hum Mol Genet 1998; 7: 517-524.
39. Falk CT, Ashley A, Lamb N, Sherman SL. Identification of susceptibility loci contributing to a complex disease using conventional segregation, linkage, and association methods. Genet Epidemiol 1995; 12: 601-606.
40. Bailly S, di Giovine FS, Duff GW. Polymorphic tandem repeat region in interleukin-1 alpha intron 6. Hum Genet 1993; 91: 85-86.
41. Kornman KS, di Giovine FS. Genetic variations in cytokine expression: a risk factor for severity of adult periodontitis. Ann Periodontol 1998; 3: 327-338.
42. Todd S, Naylor SL. Dinucleotide repeat polymorphism in the human interleukin 1, alpha gene (IL1A). Nucleic Acids Res 1991; 19: 3756.
43. Epplen C, Frank G, Gomolka M, Albert E, Nurnberg P, Epplen JT. Dinucleotide repeat polymorphism in the human IL1A gene. Hum Mol Genet 1994; 3: 1710.
44. Zuliani G, Hobbs HH. A high frequency of length polymorphisms in repeated sequences adjacent to Alu sequences. Am J Hum Genet 1990; 46: 963-969.
45. di Giovine FS, Takhsh E, Blakemore AI, Duff GW. Single base polymorphism at -511 in the human interleukin-1 beta gene (IL1 beta). Hum Mol Genet 1992; 1: 450.
46. Guasch JF, Bertina RM, Reitsma PH. Five novel intragenic dimorphisms in the human interleukin-1 genes combine to high informativity. Cytokine 1996; 8: 598-602.
47. Pociot F, Molvig J, Wogensen L, Worsaae H, Nerup J. A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest 1992; 22: 396-402.
48. Tarlow JK, Blakemore AI, Lennard A et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 1993; 91: 403-404.
49. Bergholdt R, Karlson AE, Johannesen J et al. Characterization of polymorphisms of an interleukin 1 receptor type 1 gene (IL1RI) promotor region (P2) and their relation to insulin-dependent diabetes mellitus (IDDM). The Danish Study Group of Diabetes in Childhood. Cytokine 1995; 7: 727-733.
50. John S, Turner D, Donn R et al. Two novel biallelic polymorphisms in the IL-2 gene. Eur J Immunogenet 1998; 25: 419-420.
51. Epplen C, Frank G, Gomolka M, Nagy M, Nurnberg P, Epplen JT. Dinucleotide repeat polymorphism in the IL2 and IL5RA genes. Hum Mol Genet 1994; 3: 679.
52. Cottrell S, Bodmer WF, Markie D. TaqI RFLP for the IL2RA locus. Hum Mol Genet 1994; 3: 2085.
53. Brewster ES, Brennan MB, Vissing H. Dinucleotide repeat polymorphism in the IL-2R beta gene. Nucleic Acids Res 1991; 19: 4022.
54. Jaquet K, Kreipe H, Feigner J, Radzun HJ, Parwaresch MR. A Bg1II RFLP demonstrated for the IL-3 gene in normal human blood cells and leukemias. Nucleic Acids Res 1989; 17: 3620.
55. Jeong MC, Navani A, Oksenberg JR. Limited allelic polymorphism in the human interleukin-3 gene. Molecular and Cellular Probes 1998; 12: 49-53.
56. Walley AJ, Cookson WO. Investigation of an interleukin-4 promoter polymorphism for associations with asthma and atopy. J Med Genet 1996; 33: 689-692.
57. Mout R, Willemze R, Landegent JE. Repeat polymorphisms in the interleukin-4 gene (IL4). Nucleic Acids Res 1991; 19: 3763.
58. Deichmann K, Bardutzky J, Forster J, Heinzmann A, Kuehr J. Common polymorphisms in the coding part of the IL4-receptor gene. Biochem Biophys Res Commun 1997; 231: 696-697.
59. Hershey G, Friedrich M, Esswein L, Thomas M, Chatila T. The association of atopy with a gain-of-function mutator in the a subunit of the interleukin 4 receptor. N Engl J Med 1997; 337: 1720-1725.
60. Kollintza A, Worthington J, John S, Ollier WER, Hajeer AH. A novel polymorphism in the IL-5R alpha gene promoter. Eur J Immunogenet 1998; 25: 79 (Abstract).
61. Kollintza A, Worthington J, John S, Ollier WE, Hajeer AH. A new polymorphism in the promoter of the interleukin 5 receptor alpha subunit (IL-5RA) gene. Immunogenetics 1998; 48: 65-66.
62. Olomolaiye OO, Wood NAP, Bidwell JL. Identification of a novel polymorphism in the human IL-6 promoter region. Immunology 1997; 92 (Suppl 1): 66 (Abstract 15.32).
63. Olomolaiye OO, Wood NAP, Bidwell JL. A novel NIaIII polymorphism in the human IL-6 promoter. Eur J Immunogenet 1998; 25: 267.
64. Fishman D, Faulds G, Jeffery R et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102: 1369-1376.
65. Bowcock AM, Ray A, Erlich H, Sehgal PB. Rapid detection and sequencing of alleles in the 3′ flanking region of the interleukin-6 gene. Nucleic Acids Res 1989; 17: 6855-6864.
66. Murray RE, McGuigan F, Grant SF, Reid DM, Ralston SH. Polymorphisms of the interleukin-6 gene are associated with bone mineral density. Bone 1997; 21: 89-92.
67. Fugger L, Morling N, Bendtzen K et al. MspI polymorphism in the human interleukin 6 (IL 6) gene. Nucleic Acids Res 1989; 17: 4419.
68. Blankenstein T, Volk HD, Techert-Jendrusch C, Qin ZH, Richter G, Diamantstein T. Lack of correlation between Bg1II RFLP in the human interleukin 6 gene and rheumatoid arthritis. Nucleic Acids Res 1989; 17: 8902.
69. Linker-Israeli M, Wallace DJ, Prehn JL, Nand R, Li L, Klinenberg JR. A greater variability in the 3′ flanking region of the IL-6 gene in patients with systemic lupus erythematosus (SLE). Autoimmunity 1996; 23: 199-209.
70. Tsukamoto K, Haruta K, Shiba T, Emi M. Isolation and mapping of a polymorphic CA repeat sequence at the human interleukin 6 locus. J Hum Genet 1998; 43: 71-72.
71. Tsukamoto K, Ohta N, Shirai Y, Emi M. A highly polymorphic CA repeat marker at the human interleukin 6 receptor (IL6R) locus. J Hum Genet 1998; 43: 289-290.
72. Fey MF, Tobler A. An interleukin-8 (IL-8) cDNA clone identifies a frequent HindIII polymorphism. Hum Genet 1993; 91: 298.
73. Polymeropoulos MH, Xiao H, Rath DS, Merril CR. Dinucleotide repeat polymorphism at the human interleukin 9 gene. Nucleic Acids Res 1991; 19: 688.
74. Tounas N, Cominelli F. Identification and initial characterisation of two polymorphisms in the human IL-10 promoter. European Cytokine Network 1996; 7: 578 (Abstract).
75. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997; 24: 1-8.
76. Eskdale J, Kube D, Tesch H, Gallagher G. Mapping of the human IL 10 gene and further characterization of the 5′ flanking sequence. Immunogenetics 1997; 46: 120-128.
77. Eskdale J, Gallagher G. A polymorphic dinucleotide repeat in the human IL-10 promoter. Immunogenetics 1995; 42: 444-445.
78. Eskdale J, Kube D, Gallagher G. A second polymorphic dinucleotide repeat in the 5′ flanking region of the human IL 10 gene. Immunogenetics 1996; 45: 82-83.
79. Bellingham J, Gregory-Evans K, Gregory-Evans CY. A polymorphic dinucleotide repeat in the 5′ flanking region of the human interleukin 11 (IL11) gene. Immunogenetics 1998; 47: 499-500.
80. Higuchi T, Seki N, Kamizono S et al. Polymorphism of the 5′-flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese. Tissue Antigens 1998; 51: 605-612.
81. Uglialoro AM, Turbay D, Pesavento PA et al. Identification of three new single nucleotide polymorphisms in the human tumor necrosis factor-alpha gene promoter. Tissue Antigens 1998; 52: 359-367.
82. Brinkman BM, Huizinga TW, Kurban SS et al. Tumour necrosis factor alpha gene polymorphisms in rheumatoid arthritis: association with susceptibility to, or severity of, disease? Br J Rheumatol 1997; 36: 516-521.
83. Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Putte LB, Duff GW. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 1993; 177: 557-560.
84. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997; 94: 3195-3199.
85. D'Alfonso S, Richiardi PM. A polymorphic variation in a putative regulation box of the TNFA promoter region. Immunogenetics 1994; 39: 150-154.
86. Nedospasov SA, Udalova IA, Kuprash DV, Turetskaya RL. DNA sequence polymorphism at the human tumor necrosis factor (TNF) locus. Numerous TNF/lymphotoxin alleles tagged by two closely linked microsatellites in the upstream region of the lymphotoxin (TNF-beta) gene. J Immunol 1991; 147: 1053-1059.
87. Udalova IA, Nedospasov SA, Webb GC, Chaplin DD, Turetskaya RL. Highly informative typing of the human TNF locus using six adjacent polymorphic markers. Genomics 1993; 16: 180-186.
88. Messer G, Spangler U, Jung MC et al. Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J Exp Med 1991; 173: 209-219.
89. Rink L, Kirchner H. Recent progress in the tumor necrosis factor-alpha field. Int Arch Allergy Immunol 1996; 111: 199-209.
90. Ferencik S, Lindemann M, Horsthemke B, Grosse-Wilde H. A new restriction fragment length polymorphism of the human TNF-B gene detected by AspHI digest. Eur J Immunogenet 1992; 19: 425-430.
91. Pitts SA, Olomolaiye OO, Elson CJ, Westacott CI, Bidwell JL. An MspA1 I polymorphism in exon 1 of the human TNF receptor type I (p55) gene. Eur J Immunogenet 1998; 25: 269-270.
92. Pitts SA, Olomolaiye OO, Elson CJ, Westacott CI, Bidwell JL. Identification of a rare Bg1II polymorphism in the promoter region of the human TNF receptor type I (p55) gene. Eur J Immunogenet 1998; 25: 271-272.
93. Kaufman BA, White PS, Steinbrueck T, Donis-Keller H, Brodeur GM. Linkage mapping of the tumor necrosis factor receptor 2 (TNFR2) gene to 1p36.2 using the single-strand conformation polymorphism technique. Human Genetics 1994; 94: 418-422.
94. Golovleva I, Kandefer-Szerszen M, Beckman L, Lundgren E. Polymorphism in the interferon-alpha gene family. Am J Hum Genet 1996; 59: 570-578.
95. Kwiatkowski DJ, Diaz MO. Dinucleotide repeat polymorphism at the IFNA locus (9p22). Hum Mol Genet 1992; 1: 658.
96. Vielh E, Uze G, Lutfalla G, Bandu MT, Mogensen KE. HindIII RFLP at the human IFNAR locus. Nucleic Acids Res 1990; 18: 5580.
97. Riggin CH, Jr., Pitha PM. Methylation and a polymorphic restriction site adjacent to human beta-interferon gene. DNA 1982; 1: 267-271.
98. Gray PW, Goeddel DV. Human immune interferon (IFN-gamma) gene sequence and structure. Basic Life Sciences 1983; 25: 35-61.
99. Ruiz-Linares A. Dinucleotide repeat polymorphism in the interferon-gamma (IFNG) gene. Hum Mol Genet 1993; 2: 1508.
100. Hauptschein R, Dalla-Favera R, Gaidano G. TaqI RFLP in the interferon gamma receptor 1 gene (IFNGR1) on human chromosome 6q. Nucleic Acids Res 1992; 20: 1158.
101. Hayward NK, Nancarrow DJ, Bell GI. A Taq I polymorphism for the human transforming growth factor alpha gene (TGFA). Nucleic Acids Res 1987; 15: 5303.
102. Cambien F, Ricard S, Troesch A et al. Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Temoin de l'Infarctus du Myocarde (ECTIM) Study. Hypertension 1996; 28: 881-887.
103. Awad MR, El Gamel A, Hasleton P, Sinnott P, Hutchinson IV. Polymorphism in transforming growth factor-beta 1 gene and its correlation to TGF-beta 1 production, allograft fibrosis and fibrotic lung diseases. Eur J Immunogenet 1998; 25: 70 (Abstract).
104. Langdahl BL, Knudsen JY, Jensen HK, Gregersen N, Eriksen EF. A sequence variation: 713-8delC in the transforming growth factor-beta 1 gene has higher prevalence in osteoporotic women than in normal women and is associated with very low bone mass in osteoporotic women and increased bone turnover in both osteoporotic and normal women. Bone 1997; 20: 289-294.
105. Nishimura DY, Purchio AF, Murray JC. Linkage localization of TGFB2 and the human homeobox gene HLX1 to chromosome 1q. Genomics 1993; 15: 357-364.
106. Wagner HM, Gale RE, Freeburn RW, Devereux S, Linch DC. Analysis of mutations in the GM-CSF receptor alpha coding sequence in patients with acute myeloid leukaemia and haematologically normal individuals by RT-PCR-SSCP. Leukemia 1994; 8: 1527-1532.
107. Freeburn RW, Gale RE, Linch DC. Activating point mutations in the betaC chain of the GM-CSF, IL-3 and IL-5 receptors are not a major contributory factor in the pathogenesis of acute myeloid leukaemia. Br J Haematol 1998; 103: 66-71.
108. Freeburn RW, Gale RE, Wagner HM, Linch DC. The beta subunit common to the GM-CSF, IL-3 and IL-5 receptors is highly polymorphic but pathogenic point mutations in patients with acute myeloid leukaemia (AML) are rare. Leukemia 1996; 10: 123-129.
109. Eskdale J, Gallagher C, Verweij CL, Keijsers V, Westendorp RG, Huizinga TW. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci USA 1998; 95: 9465-9470.
110. Bailly S, di Giovine FS, Blakemore AI, Duff GW. Genetic polymorphism of human interleukin-1 alpha. Eur J Immunol 1993; 23: 1240-1245.
111. Danis VA, Millington M, Hyland VJ, Grennan D. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol 1995; 99: 303-310.
112. Hurme M, Santtila S. IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1beta genes. Eur J Immunol 1998; 28: 2598-2602.
113. Pravica V, Asderakis C, Perry C, Hajeer A, Sinnott PJ, Hutchinson IV. In vitro production of IFN-γ correlates with CA repeat ' polymorphism in the human IFN-γ gene. Eur J Immunogenet 1999; 26: 1-3.
114. Awad MR, El Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV. Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 1998; 66: 1014-1020.
115. Pociot F, Briant L, Jongeneel CV et al. Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-alpha and TNF-beta by human mononuclear cells: a possible link to insulin-dependent diabetes mellitus. Eur J Immunol 1993; 23: 224-231.
116. Derkx HH, Bruin KF, Jongeneel CV. Familial differences in endotoxin-induced TNF release in whole blood and peripheral blood mononuclear cells in vitro: relationship to TNF gene polymorphism. J Endothelial Res 1995; 2: 19-25.
117. Turner DM, Grant SC, Lamb WR et al. A genetic marker of high TNF-alpha production in heart transplant recipients. Transplantation 1995; 60: 1113-1117.
118. Grove J, Daly AK, Bassendine MF, Day CP. Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology 1997; 26: 143-146.
119. Pociot FSDA, Compasso S, Scorza R, Richiardi PM. Functional analysis of a new polymorphism in the human TNF alpha gene promoter. Scand J Immunol 1995; 42: 501-504.
120. Huizinga TW, Westendorp RG, Bollen EL et al. TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. J Neuroimmunol 1997; 72: 149-153.
121. Kaijzel EL, van Krugten MV, Brinkman BM et al. Functional analysis of a human tumor necrosis factor alpha (TNF-alpha) promoter polymorphism related to joint damage in rheumatoid arthritis. Molecular Med 1998; 4: 724-733.
122. Pociot F, Wilson AG, Nerup J, Duff GW. No independent association between a tumor necrosis factor-alpha promotor region polymorphism and insulin-dependent diabetes mellitus. Eur J Immunol 1993; 23: 3050-3053.
123. Galbraith GM, Steed RB, Sanders JJ, Pandey JP. Tumor necrosis factor alpha production by oral leukocytes: influence of tumor necrosis factor genotype. J Periodontol 1998; 69: 428-433.
124. Kralovics R, Sokol L, Prchal JT. Absence of polycythemia in a child with a unique erythropoietin receptor mutation in a family with autosomal dominant primary polycythemia. J Clin Invest 1998; 102: 124-129.
125. Epplen C, Rumpf H, Albert E, Haas P, Truckenbrodt H, Epplen J. Immunoprinting excludes many potential susceptibility genes as predisposing to early onset pauciarticular juvenile chronic arthritis except HLA class II and TNF. Eur J Immunogenet 1995; 22: 311.
126. Epplen C, Jackel S, Santos EJ et al. Genetic predisposition to multiple sclerosis as revealed by immunoprinting. Ann Neurol 1997; 41: 341-352.
127. Siegmund T, Usadel KH, Donner H, Braun J, Walfish PG, Badenhoop K. Interferon-gamma gene microsatellite polymorphisms in patients with Graves' disease. Thyroid 1998; 8: 1013-1017.
128. Awata T, Matsumoto C, Urakami T, Hagura R, Amemiya S, Kanazawa Y. Association of polymorphism in the interferon gamma gene with IDDM. Diabetologia 1994; 37: 1159-1162.
129. Pociot F, Veijola R, Johannesen J et al. Analysis of an interferon-gamma gene (IFNG) polymorphism in Danish and Finnish insulin-dependent diabetes mellitus (IDDM) patients and control subjects. Danish Study Group of Diabetes in Childhood. J Interferon Cytokine Res 1997; 17: 87-93.
130. Awad MR, Pravica V, El-Gamel A, Hasleton P, Sinnott PJ, Hutchinson IV. CA repeat allele in the first intron of the interferon gamma (IFNg) gene is associated with the development of fibrosis in lung transplants. Abstracts of the British Transplantation Society 1st Annual Congress 1998.
131. Wansen K, Pastinen T, Kuokkanen S et al. Immune system genes in multiple sclerosis: genetic association and linkage analyses on TCRβ, IGH, IFNγ and IL-1Ra/IL-1β loci. J Neuroimmunol 1997; 79: 29-36.
132. He B, Xu C, Yang B, Landtblom AM, Fredrikson S, Hillert J. Linkage and association analysis of genes encoding cytokines and myelin proteins in multiple sclerosis. J Neuroimmunol 1998; 86: 13-19.
133. Asderakis A, Sankaran D, Pravica V et al. High producer interferon gamma (IFNg) and interleukin 10 (IL-10) genotype is associated with increased frequency of acute rejection episodes in kidney transplant recipients. Abstracts of the British Transplantation Society 1st Annual Congress 1998.
134. Tanaka Y, Nakashima H, Hisano C et al. Association of the interferon-gamma receptor variant (Val14Met) with systemic lupus erythematosus. Immunogenetics 1999; 49: 266-271.
135. Parkes M, Satsangi J, Jewell D. Contribution of the IL-2 and IL-10 genes to inflammatory bowel disease (IBD) susceptibility. Clin Exp Immunol 1998; 113: 28-32.
136. Eskdale J, Wordsworth P, Bowman S, Fiels M, Gallagher G. Association between polymorphisms at the IL-10 locus and systemic lupus erythematosus. Tissue Antigens 1997; 49: 635-639.
137. Mehrian R, Quismorio FP, Jr, Strassmann G et al. Synergistic effect between IL-10 and bcl-2 genotypes in determining susceptibility to systemic lupus erythematosus. Arthr Rheum 1998; 41: 596-602.
138. Allen MH, Skov L, Barber R et al. Ultraviolet B induced suppression of induction of contact sensitivity in human skin is not associated with tumour necrosis factor-alpha-308 or interleukin-10 genetic polymorphisms. Br J Dermatol 1998; 139: 225-229.
139. Middleton PG, Taylor PR, Jackson G, Proctor SJ, Dickinson AM. Cytokine gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants. Blood 1998; 92: 3943-3948.
140. Eskdale J, McNicholl J, Wordsworth P et al. Interleukin-10 microsatellite polymorphisms and IL-10 locus alleles in rheumatoid arthritis susceptibility. Lancet 1998; 352: 1282-1283.
141. Zappala F, Grove J, Watt FE et al. No evidence for involvement of the interleukin-10-592 promoter polymorphism in genetic susceptibility to primary biliary cirrhosis. J Hepatol 1998; 28: 820-823.
142. Hobbs K, Negri J, Klinnert M, Rosenwasser LJ, Borish L. Interleukin-10 and transforming growth factor-beta promoter polymorphisms in allergies and asthma. Am J Resp Crit Care Med 1998; 158: 1958-1962.
143. Lim S, Crawley E, Woo P, Barnes PJ. Haplotype associated with low interleukin-10 production in patients with severe asthma [letter]. Lancet 1998; 352: 113.
144. Hajeer AH, Lazarus M, Turner D et al. IL-10 gene promoter polymorphisms in rheumatoid arthritis. Scand J Rheumatol 1998; 27: 142-145.
145. Coakley G, Mok CC, Hajeer AH et al. Interleukin-10 promoter polymorphisms in rheumatoid arthritis and Felty's syndrome. Br J Rheumatol 1998; 37: 988-991.
146. Mok CC, Lanchbury JS, Chan DW, Lau CS. Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus. Arthritis And Rheumatism 1998; 41: 1090-1095.
147. Lazarus M, Hajeer AH, Turner D et al. Genetic variation in the interleukin 10 gene promoter and systemic lupus erythematosus. J Rheumatol 1997; 24: 2314-2317.
148. Stokkers PC, van Aken BE, Basoski N et al. Five genetic markers in the interleukin 1 family in relation to inflammatory bowel disease. Gut 1998; 43: 33-39.
149. Langabeer SE, Linch DC. IL-1 receptor antagonist gene polymorphism in patients with secondary acute myeloid leukaemia. Cytokines Cell Mol Ther 1998; 4: 7-9.
150. Takamatsu M, Yamauchi M, Maezawa Y, Ohata M, Saitoh S, Toda G. Correlation of a polymorphism in the interleukin-1 receptor antagonist gene with hepatic fibrosis in Japanese alcoholics. Alcoholism, Clin Exp Res 1998; 22: 141S-144S.
151. Tarlow JK, Clay FE, Cork MJ et al. Severity of alopecia areata is associated with a polymorphism in the interleukin-1 receptor antagonist gene. J Invest Dermatol 1994; 103: 387-390.
152. Cork MJ, Tarlow JK, Clay FE et al. An allele of the interleukin-1 receptor antagonist as a genetic severity factor in alopecia areata. J Invest Dermatol 1995; 104: 15S-16S.
153. Keen RW, Woodford-Richens KL, Lanchbury JS, Spector TD. Allelic variation at the interleukin-1 receptor antagonist gene is associated with early postmenopausal bone loss at the spine. Bone 1998; 23: 367-371.
154. Hurme M, Helminen M. Polymorphism of the IL-1 gene complex in Epstein-Barr virus seronegative and seropositive adult blood donors. Scand J Immunol 1998; 48: 219-222.
155. Blakemore AI, Watson PF, Weetman AP, Duff GW. Association of Graves' disease with an allele of the interleukin-1 receptor antagonist gene. J Clin Endocrinol Metab 1995; 80: 111-115.
156. Mühlberg T, Kirchberger M, Spitzweg C, Herrmann F, Heberling HJ, Heufelder AE. Lack of association of Graves' disease with the A2 allele of the interleukin-1 receptor antagonist gene in a white European population. Eur J Endocrinol 1998; 138: 686-690.
157. Cuddihy RM, Bahn RS. Lack of an association between alleles of interleukin-1 alpha and interleukin-1 receptor antagonist genes and Graves' disease in a North American Caucasian population. J Clin Endocrinol Metab 1996; 81: 4476-4478.
158. Liu ZH, Cheng ZH, Yu YS, Tang Z, Li LS. Interleukin-1 receptor antagonist allele: is it a genetic link between Henoch-Schonlein nephritis and IgA nephropathy? Kidney Int 1997; 51: 1938-1942.
159. Pociot F, Ronningen KS, Bergholdt R et al. Genetic susceptibility markers in Danish patients with type 1 (insulin-dependent) diabetes-evidence for polygenicity in man. Danish Study Group of Diabetes in Childhood. Autoimmunity 1994; 19: 169-178.
160. Blakemore AI, Cox A, Gonzalez AM et al. Interleukin-1 receptor antagonist allele (IL1RN*2) associated with nephropathy in diabetes mellitus. Hum Genet 1996; 97: 369-374.
161. Hacker UT, Gomolka M, Keller E et al. Lack of association between an interleukin-1 receptor antagonist gene polymorphism and ulcerative colitis. Gut 1997; 40: 623-627.
162. Hacker UT, Bidlingmaier C, Gomolka M et al. Inflammatory bowel disease: no association between allele combinations of the interleukin (IL) I beta and IL-I receptor antagonist gene polymorphisms. Eur J Clin Invest 1998; 28: 214-219.
163. Mansfield JC, Holden H, Tarlow JK et al. Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology 1994; 106: 637-642.
164. Bioque G, Bouma G, Crusius JB et al. Evidence of genetic heterogeneity in IBD: 1. The interleukin-1 receptor antagonist in the predisposition to suffer from ulcerative colitis. Eur J Gastroenterol Hepatol 1996; 8: 105-110.
165. Louis E, Satsangi J, Roussomoustakaki M et al. Cytokine gene polymorphisms in inflammatory bowel disease. Gut 1996; 39: 705-710.
166. Clay FE, Cork MJ, Tarlow JK et al. Interleukin 1 receptor antagonist gene polymorphism association with lichen sclerosus. Hum Genet 1994; 94: 407-410.
167. Bellamy R, Kwiatkowski D, Hill AV. Absence of an association between intercellular adhesion molecule 1, complement receptor 1 and interleukin 1 receptor antagonist gene polymorphisms and severe malaria in a West African population. Transactions Of The Royal Society Of Tropical Medicine And Hygiene 1998; 92: 312-316.
168. Crusius JB, Pena AS, Van Oosten BW et al. Interleukin-1 receptor antagonist gene polymorphism and multiple sclerosis. Lancet 1995; 346: 979.
169. de la Concha EG, Arroyo R, Crusius JBA et al. Combined effect of HLA-DRB1*1501 and interleukin-1 receptor antagonist gene allele 2 in susceptibility to relapsing/remitting multiple sclerosis. J Neuroimmunol 1997; 80: 172-178.
170. Huang WX, He B, Hillert J. An interleukin 1-receptor-antagonist gene polymorphism is not associated with multiple sclerosis. J Neuroimmunol 1996; 67: 143-144.
171. Semana G, Yaouanq J, Alizadeh M, Clanet M, Edan G. Interleukin-1 receptor antagonist gene in multiple sclerosis. Lancet 1997; 349: 476.
172. Huang D, Pirskanen R, Hjelmström P, Lefvert AK. Polymorphisms in IL-1 beta and IL-1 receptor antagonist genes are associated with myasthenia gravis. J Neuroimmunol 1998; 81: 76-81.
173. Perrier S, Coussediere C, Dubost JJ, Albuisson E, Sauvezic B. IL-1 receptor antagonist (IL-1RA) gene polymorphism in Sjögren's syndrome and rheumatoid arthritis. Clin Immunol Immunopath 1998; 87: 309-313.
174. Francis SE, Camp NJ, Dewberry RM et al. Interleukin-1 receptor antagonist gene polymorphism and coronary heart disease. Circulation 1999; 99: 861-866.
175. Blakemore AI, Tarlow JK, Cork MJ, Gordon C, Emery P, Duff GW. Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus. Arthritis Rheum 1994; 37: 1380-1385.
176. Suzuki H, Matsui Y, Kashiwagi H. Interleukin-1 receptor antagonist gene polymorphism in Japanese patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 389-390.
177. Danis VA, Millington M, Huang Q, Hyland V, Grennan D. Lack of association between an interleukin-1 receptor antagonist gene polymorphism and systemic lupus erythematosus. Dis Markers 1995; 12: 135-139.
178. Bouma G, Crusius JB, García-González MA et al. Genetic markers in clinically well defined patients with ulcerative colitis (UC). Clin Exp Immunol 1999; 115: 294-300.
179. Metcalfe KA, Hitman GA, Pociot F et al. An association between type 1 diabetes and the interleukin-1 receptor type 1 gene. The DiMe Study Group. Childhood Diabetes in Finland. Hum Immunol 1996; 51: 41-48.
180. Gomolka M, Menninger H, Saal JE et al. Immunoprinting: various genes are associated with increased risk to develop rheumatoid arthritis in different groups of adult patients. J Mol Med 1995; 73: 19-29.
181. McDowell TL, Symons JA, Ploski R, Forre O, Duff GW. A genetic association between juvenile rheumatoid arthritis and a novel interleukin-1 alpha polymorphism. Arthritis Rheum 1995; 38: 221-228.
182. Bailly S, Hayem G, Fay M, Kahn MF, Gougerot-Pocidalo MA. Absence of correlation between IL-1 alpha intron 6 polymorphism and rheumatoid arthritis. Br J Rheumatol 1995; 34: 1123-1126.
183. Kornman KS, Crane A, Wang HY et al. The interleukin-1 genotype as a severity factor in adult periodontal disease. J Clin Periodontol 1997; 24: 72-77.
184. Bloque G, Crusius JB, Koutroubakis I et al. Allelic polymorphism in IL-1 beta and IL-1 receptor antagonist (IL-1Ra) genes in inflammatory bowel disease. Clin Exp Immunol 1995; 102: 379-383.
185. Heresbach D, Alizadeh M, Dabadie A et al. Significance of interleukin-1beta and interleukin-1 receptor antagonist genetic polymorphism in inflammatory bowel diseases. Am J Gastroenterol 1997; 92: 1164-1169.
186. Lanng S, Thorsteinsson B, Pociot F et al. Diabetes mellitus in cystic fibrosis: genetic and immunological markers. Acta Paediatr 1993; 82: 150-154.
187. Loughrey BV, Maxwell AP, Fogarty DG et al. An interleukin 1B allele, which correlates with a high secretor phenotype, is associated with diabetic nephropathy. Cytokine 1998; 10: 984-988.
188. Majeed GS, Glew S, Bidwell J. An association between LSIL and the high secretor phenotype of IL-1β. Gynecol Oncol 1999; 73: 359-361.
189. Gore EA, Sanders JJ, Pandey JP, Palesch Y, Galbraith GM. Interleukin-1beta+3953 allele 2: association with disease status in adult periodontitis. J Clin Periodontol 1998; 25: 781-785.
190. Katila H, Hanninen K, Hurme M. Polymorphisms of the interleukin-1 gene complex in schizophrenia. Mol Psychiatry 1999; 4: 179-181.
191. Nimgaonkar VL, Yang ZW, Zhang XR, Brar JS, Chakravarti A, Ganguli R. Association study of schizophrenia and the IL-2 receptor beta chain gene. Am J Med Genet 1995; 60: 448-451.
192. Tatsumi M, Sasaki T, Sakai T et al. Genes for interleukin-2 receptor beta chain, interleukin-1 beta, and schizophrenia: no evidence for the association or linkage. Am J Med Genet 1997; 74: 338-341.
193. Clark PA, Lester T, Genet S et al. Screening for mutations causing X-linked severe combined immunodeficiency in the IL-2R gamma chain gene by single-strand conformation polymorphism analysis. Hum Genet 1995; 96: 427-432.
194. Pepper AE, Buckley RH, Small TN, Puck JM. Two mutational hotspots in the interleukin-2 receptor gamma chain gene causing human X-linked severe combined immunodeficiency. Am J Hum Genet 1995; 57: 564-571.
195. Puck JM, Pepper AE, Bedard PM, Laframboise R. Female germ line mosaicism as the origin of a unique IL-2 receptor gamma-chain mutation causing X-linked severe combined immunodeficiency. J Clin Invest 1995; 95: 895-899.
196. O'Marcaigh AS, Puck JM, Pepper AE, De Santes K, Cowan MJ. Maternal mosaicism for a novel interleukin-2 receptor gamma-chain mutation causing X-linked severe combined immunodeficiency in a Navajo kindred. J Clin Immunol 1997; 17: 29-33.
197. Puck JM, Middelton L, Pepper AE. Carrier and prenatal diagnosis of X-linked severe combined immunodeficiency: mutation detection methods and utilization. Hum Genet 1997; 99: 628-633.
198. Puck JM, Pepper AE, Henthorn PS et al. Mutation analysis of IL2RG in human X-linked severe combined immunodeficiency. Blood 1997; 89: 1968-1977.
199. Wengler GS, Giliano S, Fiorini M et al. Mutation analysis by a non-radioactive single-strand conformation polymorphism assay in nine families with X-linked severe combined immunodeficiency (SCIDX1). Br J Haematol 1998; 101: 586-591.
200. Fugmann SD, Müller S, Friedrich W, Bartram CR, Schwarz K. Mutations in the gene for the common gamma chain (gammac) in X-linked severe combined immunodeficiency. Human Genetics 1998; 103: 730-731.
201. Noguchi E, Shibasaki M, Arinami T et al. Association of asthma and the interleukin-4 promoter gene in Japanese. Clin Exp Allergy 1998; 28: 449-153.
202. Kawashima T, Noguchi E, Arinami T et al. Linkage and association of an interleukin 4 gene polymorphism with atopic dermatitis in Japanese families. J Med Genet 1998; 35: 502-504.
203. Vandenbroeck K, Martino G, Marrosu M et al. Occurrence and clinical relevance of an interleukin-4 gene polymorphism in patients with multiple sclerosis. J Neuroimmunol 1997; 76: 189-192.
204. Huang D, Xia S, Zhou Y, Pirskanen R, Liu L, Lefvert AK. No evidence for interleukin-4 gene conferring susceptibility to myasthenia gravis. J Neuroimmunol 1998; 92: 208-211.
205. Mitsuyasu H, Izuhara K, Mao X-Q et al. I1e50Val variant of IL4Rα upregulates IgE synthesis and associates with atopic asthma. Nature Genetics 1998; 19: 119-120.
206. Izuhara K, Shirakawa T. Signal transduction via the interleukin-4 receptor and its correlation with atopy. Int J Mol Med 1999; 3: 3-10.
207. Fugger L, Morling N, Bendtzen K et al. IL-6 gene polymorphism in rheumatoid arthritis, pauciarticular juvenile rheumatoid arthritis, systemic lupus erythematosus, and in healthy Danes. J Immunogenet 1989; 16: 461-465.
208. Scapoli L, Pezzetti F, Carinci F, Martinelli M, Carinci P, Tognon M. Lack of linkage disequilibrium between transforming growth factor alpha Taq I polymorphism and cleft lip with or without cleft palate in families from Northeastern Italy. Am J Med Genet 1998; 75: 203-206.
209. Syrris P, Carter ND, Metcalfe JC et al. Transforming growth factor-beta1 gene polymorphisms and coronary artery disease. Clin Sci (Colch) 1998; 95: 659-667.
210. Pociot F, Hansen P, Karlsen A, Langdahl B, Johannnesen J, Nerup J. Transforming growth factor-beta 1 gene mutations in insulin-dependent diabetes mellitus (IDDM) and diabetic nephropathy. J Am Soc Nephrol 1998; 9: 2302-2307.
211. Yamada Y, Miyauchi A, Goto J et al. Association of a polymorphism of the transforming growth factor-betal 1 gene with genetic susceptibility to osteoporosis in postmenopausal Japanese women. J Bone Miner Res 1998; 13: 1569-1576.
212. Li B, Khanna A, Sharma V, Singh T, Suthanthiran M, August P. TGF-beta1 DNA polymorphisms, protein levels and blood pressure. Hypertension 1999; 33: 271-275.
213. Sandberg-Wollheim M, Ciusani E, Salmaggi A, Pociot F. An evaluation of tumour necrosis factor microsatellite alleles in genetic susceptibility to multiple sclerosis. Multiple Sclerosis: Clin Lab Res 1995; 1: 181-185.
214. Matthias C, Jahnke V, Fryer A, Strange R, Ollier W, Hajeer A. Influence of tumour necrosis factor microsatellite polymorphisms on susceptibility to head and neck cancer. Acta Otolaryngol (Stockh) 1998; 118: 284-288.
215. Monos DS, Kamoun M, Udalova IA et al. Genetic polymorphism of the human tumor necrosis factor region in insulin-dependent diabetes mellitus. Linkage disequilibrium of TNFab microsatellite alleles with HLA haplotypes. Hum Immunol 1995; 44: 70-79.
216. Hajeer AH, Worthington J, Silman AJ, Ollier WE. Association of tumor necrosis factor microsatellite polymorphisms with HLA-DRBI *04-bearing haplotypes in rheumatoid arthritis patients. Arthritis Rheum 1996; 39: 1109-1114.
217. Ma JJ, Nishimura M, Minc H et al. Genetic contribution of the tumor necrosis factor region in Guillain-Barre syndrome. Ann Neurol 1998; 44: 815-818.
218. Gallagher G, Lindemann M, Oh H-H et al. Association of the TNFa2 microsatellite allele with the presence of colorectal cancer. Tissue Antigens 1998; 50: 47-51.
219. Hjelmstrom P, Peacock CS, Giscombe R et al. Polymorphism in tumor necrosis factor genes associated with myasthenia gravis. J Neuroimmunol 1998; 88: 137-143.
220. Polvi A, Maki M, Collin P, Partanen J. TNF microsatellite alleles a2 and b3 are not primarily associated with celiac disease in the Finnish population. Tissue Antigens 1998; 51: 553-555.
221. Mulcahy B, Waldron-Lynch F, McDermott MF et al. Genetic variability in the tumor necrosis factor-lymphotoxin region influences susceptibility to rheumatoid arthritis. Am J Hum Genet 1996; 59: 676-683.
222. Asano H et al. Significance of tumor necrosis factor microsatellite polymorphism in renal transplantation. Tissue Antigens 1997; 50: 484-488.
223. Turbay D, Lieberman J, Alper CA et al. Tumor necrosis factor constellation polymorphism and clozapine-induced agranulocytosis in two different ethnic groups. Blood 1997; 89: 4167-4174.
224. Khoo SH, Pepper L, Snowden N et al. Tumour necrosis factor c2 microsatellite allele is associated with the rate of HIV disease progression. AIDS 1997; 11: 423-428.
225. McDermot MF, Aksentijevich I, Galon J et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999; 97: 133-144.
226. Rau H, Donner H, Usadel K, Badenhoop K. Polymorphisms of tumor necrosis factor receptor 2 are not associated with insulin-dependant diabetes mellitus or Grave's disease. Tissue Antigens 1997; 49: 535-536.
227. Hamann A, Mantzoros C, Vidal-Puig A, Flier JS. Genetic variability in the TNF-alpha promoter is not associated with type II diabetes mellitus (NIDDM). Biochem Biophys Res Comm 1995; 211: 833-839.
228. Höhler T, Kruger A, Gerken G et al. A tumor necrosis factor-alpha (TNF-alpha) promoter polymorphism is associated with chronic hepatitis B infection. Clin Exp Immunol 1998; 111: 579-582.
229. Höhler T, Kruger A, Gerken G et al. Tumor necrosis factor alpha promoter polymorphism at position -238 is associated with chronic active hepatitis C infection. J Med Virol 1998; 54: 173-177.
230. Jacob N, Ruschendorf F, Schmitt-Egenolf M et al. Promoter polymorphism at -238 of the tumor necrosis factor alpha gene is not associated with early onset psoriasis when tested by the transmission disequilibrium test. J Invest Dermatol 1999; 112: 514-516.
231. Day CP, Grove J, Daly AK, Stewart MW, Avery PJ, Walker M. Tumour necrosis factor-alpha gene promoter polymorphism and decreased insulin resistance. Diabetologia 1998; 41: 430-434.
232. Vinasco J, Beraun Y, Nieto A et al. Polymorphism at the TNF loci in rheumatoid arthritis. Tissue Antigens 1997; 49: 74-78.
233. Conway DJ, Holland MJ, Bailey RL et al. Scarring trachoma is associated with polymorphism in the tumor necrosis factor alpha (TNF-alpha) gene promoter and with elevated TNF-alpha levels in tear fluid. Infect Immun 1997; 65: 1003-1006.
234. Beraun Y, Nieto A, Collado MD, Gonzalez A, Martin J. Polymorphisms at tumor necrosis factor (TNF) loci are not associated with Chagas' disease. Tissue Antigens 1998; 52: 81-83.
235. Fraile A, Nieto A, Beraun Y, Vinasco J, Mataran L, Martin J. Tumor necrosis factor gene polymorphisms in ankylosing spondylitis. Tissue Antigens 1998; 51: 386-390.
236. Zhai R, Jetten M, Schins RP, Franssen H, Borm PJ. Polymorphisms in the promoter of the tumor necrosis factor-alpha gene in coal miners. Am J Ind Med 1998; 34: 318-324.
237. Westendorp RG, Langermans JA, Huizinga TW et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997; 349: 170-173.
238. Rudwaleit M, Tikly M, Khamashta M et al. Interethnic differences in the association of tumor necrosis factor promoter polymorphisms with systemic lupus erythematosus. J Rheumatol 1996; 23: 1725-1728.
239. D'Alfonso S, Colombo G, Della Bella S et al. Association between polymorphisms in the TNF region and systemic lupus erythematosus in the Italian population. Tissue Antigens 1996; 47: 551-555.
240. Carey BS, Grabczynska SA, McGregor J, Hawk JLM, Vaughan RW. The association of DR4 with AP is not influenced by the -308 TNF alpha promoter polymorphism. Eur J Immunogenet 1998; 25: 55 (Abstract).
241. Verjans GM, Brinkman BM, Van Doomik CE, Kijlstra A, Verweij CL. Polymorphism of tumour necrosis factor-alpha (TNF-alpha) at position -308 in relation to ankylosing spondylitis. Clin Exp Immunol 1994; 97: 45-47.
242. Manus RM, Wilson AG, Mansfield J, Weir DG, Duff GW, Kelleher D. TNF2, a polymorphism of the tumor necrosis-alpha gene promoter, is a component of the celiac disease major histocompatibility complex haplotype. Eur J Immunol 1996; 26: 2113-2118.
243. McGuire W, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski D. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature 1994; 371: 508-510.
244. Demeter J, Porzsolt F, Ramisch S, Schmidt D, Schmid M, Messer G. Polymorphism of the tumour necrosis factor-alpha and lymphotoxin-alpha genes in chronic lymphocytic leukaemia. Br J Haematol 1997; 97: 107-112.
245. Wihlborg C, Sjoberg J, Intaglietta M, Axdorph U, Pisa EK, Pisa P. Tumour necrosis factor-alpha cytokine promoter gene polymorphism in Hodgkin's disease and chronic lymphocytic leukaemia. Br J Haematol 1999; 104: 346-349.
246. Herrmann SM, Ricard S, Nicaud V et al. Polymorphisms of the tumour necrosis factor-alpha gene, coronary heart disease and obesity. Eur J Clin Invest 1998; 28: 59-66.
247. Wilson AG, Clay FE, Crane AM, Cork MJ, Duff GW. Comparative genetic association of human leukocyte antigen class II and tumor necrosis factor-alpha with dermatitis herpetiformis. J Invest Dermatol 1995; 104: 856-858.
248. Mayer FR, Messer G, Knabe W et al. High response of TNFα secretion in vivo in patients undergoing BMT may be associated with the -308 TNFa gene enhancer polymorphism. Bone Marrow Transplant 1996; 17: (Suppl 1): 101.
249. Sato-Matsumura KC, Berger J, Hainfellner JA, Mazal P, Budka H. Development of HIV encephalitis in AIDS and TNF-alpha regulatory elements. J Neuroimmunol 1998; 91: 89-92.
250. Deng GY, Maclaren NK, Huang HS, Zhang LP, She JX. No primary association between the 308 polymorphism in the tumor necrosis factor alpha promoter region and insulin-dependent diabetes mellitus. Hum Immuno 1996; 45: 137-142.
251. Roy S, McGuire W, Mascie-Taylor CG et al. Tumor necrosis factor promoter polymorphism and susceptibility to lepromatous leprosy. J Infect Dis 1997; 176: 530-532.
252. Clay FE, Cork MJ, Wilson AG et al. Promoter region polymorphism in the human TNF-alpha gene is not associated with lichen sclerosus. Exp Dermatol 1996; 5: 227-229.
253. He B, Navikas V, Lundahl J, Soderstrom M, Hillert J. Tumor necrosis factor alpha-308 alleles in multiple sclerosis and optic neuritis. J Neuroimmunol 1995; 63: 143-147.
254. Wingerchuck D, Liu Q, Sobell J, Sommer S, Weinshenker B. A population-based case-control study of the tumor necrosis factor alpha-308 polymorphism in multiple sclerosis. Neurology 1997; 49: 626.
255. Kanerva M, Vaheri A, Mustonen J, Partanen J. High-producer allele of tumour necrosis factor-alpha is part of the susceptibility MHC haplotype in severe puumala virus-induced nephropathia epidemica. Scand J Infect Dis 1998; 30: 532-534.
256. Bernal W, Moloney M, Underhill J, Donaldson PT. Association of tumor necrosis factor polymorphism with primary sclerosing cholangitis. J Hepatol 1999; 30: 237-241.
257. Wilson AG, Gordon C, di Giovine FS et al. A genetic association between systemic lupus erythematosus and tumor necrosis factor alpha. Eur J Immunol 1994; 24: 191-195.
258. Danis VA, Millington M, Hyland V, Lawford R, Huang Q, Grennan D. Increased frequency of the uncommon allele of a tumour necrosis factor alpha gene polymorphism in rheumatoid arthritis and systemic lupus erythematosus. Dis Markers 1995; 12: 127-133.
259. Wattavidanage J, Carter R, Perera KL et al. TNFalpha*2 marks high risk of severe disease during Plasmodium falciparum malaria and other infections in Sri Lankans. Clin Exp Immunol 1999; 115: 350-355.
260. Stuber F, Udalova IA, Book M et al. -308 tumor necrosis factor (TNF) polymorphism is not associated with survival in severe sepsis and is unrelated to lipopolysaccharide inducibility of the human TNF promoter. J Inflamm 1995; 46: 42-50.
261. Kim HY, Lee SH, Yang HI et al. TNFB gene polymorphism in patients with systemic lupus erythematosus in Korean. Korean J Intern Med 1995; 10: 130-136.
262. Kim TG, Kim HY, Lee SH et al. Systemic lupus erythematosus with nephritis is strongly associated with the TNFB*2 homozygote in the Korean population. Hum Immunol 1996; 46: 10-17.
263. Sullivan K, Wooten C, Schmeekpeper B, Goldman D, Petri M. A promoter polymorphism of tumor necrosis factor alpha associated with systemic lupus erythematosus in African-Americans. Arthr Rheum 1997; 40: 2207-2211.
264. Fong KY, Howe HS, Tin SK, Boey ML, Feng PH. Polymorphism of the regulatory region of tumour necrosis factor alpha gene in patients with systemic lupus erythematosus. Ann Acad Med Singapore 1996; 25: 90-93.
265. Brown K, Luddington R, Baglin T. A common polymorphism in the tumour necrosis factor-alpha gene associated with high TNF levels is not a risk factor for venous thromboembolism. Br J Haematol 1998; 101: 480-482.
266. Turner D, Grant S, Yonan N et al. Cytokine gene polymorphism and heart transplant rejection. Transplantation 1997; 64: 776-779.
267. Sankaran D, Ashraf S, Asderakis A et al. Tumour necrosis factor alpha (TNFa) and interleukin-10 (IL-10) gene polymorphisms predict acute renal allograft rejection. Abstracts of the British Transplantation Society 1st Annual Congress 1998.
268. Sankaran D, Ashraf S, Martin S et al. High interleukin-10 producer genotype is not protective against renal allograft rejection in high TNFα producers. Eur J Immunogenet 1998; 25: 68 (Abstract).
269. Moffatt MF, Cookson WO. Tumour necrosis factor haplotypes and asthma. Hum Mol Genet 1997; 6: 551-554.
270. Trabetti E, Patuzzo C, Malerba G et al. Association of a lymphotoxin alpha gene polymorphism and atopy in Italian families. J Med Genet 1999; 36: 323-325.
271. Albuquerque RV, Hayden CM, Palmer LJ et al. Association of polymorphisms within the tumour necrosis factor (TNF) genes and childhood asthma. Clin Exp Allergy 1998; 28: 578-584.
272. Park KS, Mok JW, Rho SA, Kim JC. Analysis of TNFB and TNFA Ncol RFLP in colorectal cancer. Mol Cells 1998; 8: 246-249.
273. Kubota T, McNamara DM, Wang JJ et al. Effects of tumor necrosis factor gene polymorphisms on patients with congestive heart failure. VEST Investigators for TNF Genotype Analysis. Vesnarinone Survival Trial. Circulation 1998; 97: 2499-2501.
274. Messer G, Kick G, Ranki A, Koskimies S, Reunala T, Meurer M. Polymorphism of the tumor necrosis factor genes in patients with dermatitis herpetiformis. Dermatology 1994; 189: (Suppl 1): 135-137.
275. Demeter J, Porzsolt F, Ramisch S, Schmid M, Messer G. Polymorphism of the tumour necrosis factor-alpha and lymphotoxin-alpha genes in hairy cell leukaemia. Br J Haematol 1997; 97: 132-134.
276. Mycko M, Kowalski W, Kwinkowski M et al. Multiple sclerosis: the frequency of allelic forms of tumor necrosis factor and lymphotoxin-alpha. J Neuroimmunol 1998; 84: 198-206.
277. Warzocha K, Ribeiro P, Bienvu J et al. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood 1998; 91: 3574-3581.
278. Cabrera M, Shaw MA, Sharples C et al. Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis. J Exp Med 1995; 182: 1259-1264.
279. Mullighan CG, Fanning GC, Chapel HM, Welsh KI. TNF and lymphotoxin-alpha polymorphisms associated with common variable immunodeficiency: role in the pathogenesis of granulomatous disease. J Immunol 1997; 159: 6236-6241.
280. Verjans GM, van der Linden SM, van Eys GJ, de Waal LP, Kijlstra A. Restriction fragment length polymorphism of the tumor necrosis factor region in patients with ankylosing spondylitis. Arthritis Rheum 1991; 34: 486-489.
281. Chung JH, Cho BY, Lee HK, Kim TG, Han H, Koh CS. The tumor necrosis factor beta* 1 allele is linked significantly to HLA-DR8 in Koreans with atrophic autoimmune thyroiditis who are positive for thyrotropin receptor blocking antibody. J Korean Med Sci 1994; 9: 155-161.
282. Shimura T, Hagihara M, Takebe K et al. 10.5-kb homozygote of tumor necrosis factor-beta gene is associated with a better prognosis in gastric cancer patients. Cancer 1995; 75: 1450-1453.
283. Badenhoop K, Schwarz G, Schleusener H et al. Tumor necrosis factor beta gene polymorphisms in Graves' disease. J Clin Endocrinol Metab 1992; 74: 287-291.
284. Badenhoop K, Schwarz G, Walfish PG, Drummond V, Usadel KH, Bottazzo GF. Susceptibility to thyroid autoimmune disease: molecular analysis of HLA-D region genes identifies new markers for goitrous Hashimoto's thyroiditis. J Clin Endocrinol Metab 1990; 71: 1131-1137.
285. Braun J, Marz W, Winkelmann BR, Donner H, Usadel K, Badenhoop K. Tumour necrosis factor beta alleles and hyperinsulinaemia in coronary artery disease. Eur J Clin Invest 1998; 28: 538-542.
286. Badenhoop K, Schwarz G, Bingley P et al. TNF-alpha gene polymorphisms: association with type 1 (insulin-dependent) diabetes mellitus. J Immunogenet 1989; 16: 455-460.
287. Badenhoop K, Schwartz G, Trowsdale J et al. TNF-alpha gene polymorphisms in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1989; 32: 445-448.
288. Badenhoop K. Immunogenetic markers for autoimmune diseases of the endocrine system. Klin Wochenschr 1990; 68 (Suppl 21): 10-14.
289. Jenkins D, Penny MA, Mijovic CH, Jacobs KH, Fletcher J, Barnett AH. Tumour necrosis factor-beta polymorphism is unlikely to determine susceptibility to type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1991; 34: 576-578.
290. Pociot F, Molvig J, Wogensen L et al. A tumour necrosis factor beta gene polymorphism in relation to monokine secretion and insulindependent diabetes mellitus. Scand J Immunol 1991; 33: 37-49.
291. Yamagata K, Hanafusa T, Nakajima H et al. HLA-DQA1*1 contributes to resistance and A1*3 confers susceptibility to type 1 (insulin-dependent) diabetes mellitus in Japanese subjects. Diabetologia 1991; 34: 133-136.
292. Ilonen J, Merivuori H, Reijonen H et al. Tumour necrosis factor-beta gene RFLP alleles in Finnish IDDM haplotypes. The Child-. hood Diabetes in Finland (DiMe) Study Group. Scand J Immunol 1992; 36: 779-783.
293. Feugeas JP, Dosquet C, Wautier JL, Montchamp-Moreau C, Krishnamoorthy R, Caillens H. Dysregulation of in vitro TNF-beta production in insulin-dependent diabetes mellitus. C R Acad Sci III 1993; 316: 1255-1259.
294. Vendrell J, Ercilla G, Gutierrez C et al. A tumor necrosis factor beta-gene polymorphism associated with islet cell antibodies in newly diagnosed type I diabetic patients. Diabetes Care 1994; 17: 944-945.
295. Whichelow CE, Hitman GA, Raafat I, Bottazzo GF, Sachs JA. The effect of TNF*B gene polymorphism on TNF-alpha and -beta secretion levels in patients with insulin-dependent diabetes mellitus and healthy controls. Eur J Immunogenet 1996; 23: 425-435.
296. Medcraft J, Hitman GA, Sachs JA, Whichelow CE, Raafat I, Moore RH. Autoimmune renal disease and tumour necrosis factor beta gene polymorphism. Clin Nephrol 1993; 40: 63-68.
297. Xia B, Bouma G, Grusius JB, Meuwissen SG, Pena AS. Distribution of an NcoI polymorphism in the lymphotoxin alpha gene in Dutch patients with inflamatory bowel diseases. Chin Med J (Engl) 1995; 108: 739-742.
298. Shimura T, Haihara M, Takebe K et al. The study of tumor necrosis factor beta gene polymorphism in lung cancer patients. Cancer 1994; 73: 1184-1188.
299. Hagihara M, Shimura T, Sato K, Genga K, Suzuki M, Tsuji K. HLA and tumor necrosis factor beta gene polymorphisms in Okinawa lung cancer patients: comparative study with mainland Japan lung cancer patients. Hum Immunol 1995; 43: 95-100.
300. Fugger L, Morling N, Sandberg-Wollheim M, Ryder LP, Svejgaard A. Tumor necrosis factor alpha gene polymorphism in multiple sclerosis and optic neuritis. J Neuroimmunol 1990; 27: 85-88.
301. Zelano G, Lino MM, Evoli A et al. Tumour necrosis factor beta gene polymorphisms in myasthenia gravis. Eur J Immunogenet 1998; 25: 403-408.
302. Vendrell J, Gutierrez C, Pastor R, Richart C. A tumor necrosis factor-beta polymorphism associated with hypertriglyceridemia in non-insulin-dependent diabetes mellitus. Metabolism 1995; 44: 691-694.
303. Fugger L, Morling N, Ryder LP et al. NcoI restriction fragment length polymorphism (RFLP) of the tumour necrosis factor (TNF alpha) region in primary biliary cirrhosis and in healthy Danes. Scand J Immunol 1989; 30: 185-189.
304. Messer G, Spengler U, Jung MC et al. Allelic variation in the TNF-beta gene does not explain the low TNF-beta response in patients with primary biliary cirrhosis. Scand J Immunol 1991; 34: 735-740.
305. Fugger L, Morling N, Ryder LP et al. NcoI restriction fragment length polymorphism (RFLP) of the tumor necrosis factor (TNF alpha) region in four autoimmune diseases. Tissue Antigens 1989; 34: 17-22.
306. Atsumi T. Tumor necrosis factor alpha in systemic lupus erythematosus: evaluation by restriction fragment length polymorphism and production by peripheral blood mononuclear cells. Hokkaido Igaku Zasshi 1992; 67: 408-419.
307. Bettinotti MP, Hartung K, Deicher H et al. Polymorphism of the tumor necrosis factor beta gene in systemic lupus erythematosus: TNFB-MHC haplotypes. Immunogenetics 1993; 37: 449-454.
308. Campbell DA, Nelson S, Madhok R, Field M, Gallagher G. TNF Nco-I RFLP is not an independent risk factor in rheumatoid arthritis. Eur J Immunogenet 1994; 21: 461-467.
309. Vandevyver C, Raus P, Stinissen P, Philippaerts L, Cassiman JJ, Raus J. Polymorphism of the tumour necrosis factor beta gene in multiple sclerosis and rheumatoid arthritis. Eur J Immunogenet 1994; 21: 377-382.
310. Laitinen T, Lokki ML, Tulppala M, Ylikorkala O, Koskimies S. Tumour necrosis factor B gene polymorphism in relation to complotype in couples with spontaneous abortions and in control families. Scand J Immunol 1992; 35: 131-135.
311. Mizuki N, Inoko H, Sugimura K et al. RFLP analysis in the TNF-beta gene and the susceptibility to alloreactive NK cells in Behcet's disease. Invest Ophthalmol Vis Sci 1992; 33: 3084-3090.
312. Roth MP, Nogueira L, Coppin H, Clanet M, Clayton J, Cambon-Thomsen A. Tumor necrosis factor polymorphism in multiple sclerosis: no additional association independent of HLA. J Neuroimmunol 1994; 51: 93-99.
313. Petrovsky N, Harrison LC. Diurnal rhythmicity of human cytokine production - A dynamic disequilibrium in T helper cell type 1/T helper cell type 2 balance? J Immunol 1997; 158: 5163-5168.
314. Petrovsky N, Harrison LC. HLA-class 11-associated polymorphism of interferon-gamma production. Implications for HAL-disease association. Hum Immunol 1997; 53: 12-16.
315. Mineta M, Tanimura M, Tana T, Yssel H, Kashiwagi S, Sasazuki T. Contribution of HLA class I and class II alleles to the regulation of antibody production to hepatitis B surface antigen in humans. Int Immunol 1996; 8: 525-531.
316. Candore G, Cigna D, Todaro M et al. T-cell activation in HLA-B8, DR3-positive individuals. Early antigen expression defect in vitro. Hum Immunol 1995; 42: 289-294.
317. Caruso C, Candore G, Modica MA et al. Major histocompatibility complex regulation of cytokine production. J Interferon Cytokine Res 1996; 16: 983-988.
318. Lio D, Candore G, Romano GC et al. Modification of cytokine secretion patterns in subjects bearing the HLA-B8,DR3 phenotype: implications for autoimmunity. Cytokines Cell Mol Ther 1997; 3: 217-224.
319. Stassi G, Todaro M, De Maria R et al. Defective expression of CD95 (FAS/APO-1) molecule suggests apoptosis impairment of T and B cells in HLA-B8,DR3-positive individuals. Hum Immunol 1997; 55: 39-45.
320. Caruso C, Bongiardina C, Candore G et al. HLA-B8,DR3 haplotype affects lymphocyte blood levels. Immunol Invest 1997; 26: 333-340.
321. Fleury S, Thibodeau J, Croteau G et al. HLA-DR polymorphism affects the interaction with DR4. J Exp Med 1995; 182: 733-741.
322. Lio D, Candore G, Cigna D et al. In vitro T-cell activation in elderly individuals: failure in CD69 and CD71 expression. Mech Ageing Dev 1996; 89: 51-58.
323. Pawelec G, Effros RB, Caruso C, Remarque E, Banett Y, Solana R. T-cells and ageing (update 1999). Front Biosci 1999; 4: D216-269.